Pfizer’s Xalkori Joins The Six-Figure Oncology Drug Club
The roll-out of Pfizer Inc.’s new personalized non-small cell lung cancer therapy Xalkori blends right in with the prevailing trends in cancer drug launches, proving that six-figure pricing now seems to be the new black in oncology.
You may also be interested in...
Oncology PROs: Limited Use Due To Small Trials, Fast Drug Development
Patient-reported outcomes in oncology clinical trials remain an infrequently used tool, despite acknowledgement by sponsors that the patient experience is important to measure – and encouragement from FDA officials to do so. The lack of PROs in oncology may be a byproduct of the fast pace of cancer drugs are developed in the U.S.: small trials and accelerated pathways.
Genentech’s Alecensa Joins The ALK Inhibitor Market
Alectinib will launch within two weeks for second-line ALK-positive non-small lung cancer at the price of $12,500 per month.
Questioning Stivarga’s Cost-Effectiveness In Colon Cancer
The high cost of colon cancer drugs is once again under fire, this time with Bayer and Onyx in the hot seat. In a Lancet editorial accompanying pivotal trial results for regorafenib, U.K. authors doubt the modestly efficacious drug will ever prove cost-effectiveness in colon cancer, but that its role in GIST looks more compelling.